DE69634627D1 - Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung - Google Patents

Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung

Info

Publication number
DE69634627D1
DE69634627D1 DE69634627T DE69634627T DE69634627D1 DE 69634627 D1 DE69634627 D1 DE 69634627D1 DE 69634627 T DE69634627 T DE 69634627T DE 69634627 T DE69634627 T DE 69634627T DE 69634627 D1 DE69634627 D1 DE 69634627D1
Authority
DE
Germany
Prior art keywords
rantes
mip
mcp
alpha
1alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69634627T
Other languages
English (en)
Other versions
DE69634627T2 (de
DE69634627T3 (de
Inventor
Timothy Nigel Carl Wells
Christine Anna Power
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69634627(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE69634627D1 publication Critical patent/DE69634627D1/de
Publication of DE69634627T2 publication Critical patent/DE69634627T2/de
Application granted granted Critical
Publication of DE69634627T3 publication Critical patent/DE69634627T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
DE69634627T 1995-01-27 1996-01-24 Ein Chemokin Rezeptor für MCP-1, MIP-1 alpha und/oder RANTES Expired - Lifetime DE69634627T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9501683 1995-01-27
GBGB9501683.8A GB9501683D0 (en) 1995-01-27 1995-01-27 Substances and their uses
PCT/GB1996/000143 WO1996023068A1 (en) 1995-01-27 1996-01-24 A chemokine receptor able to bind to mcp-1, mip-1 alpha and/or rantes. its uses

Publications (3)

Publication Number Publication Date
DE69634627D1 true DE69634627D1 (de) 2005-05-25
DE69634627T2 DE69634627T2 (de) 2006-03-02
DE69634627T3 DE69634627T3 (de) 2008-12-11

Family

ID=10768728

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634627T Expired - Lifetime DE69634627T3 (de) 1995-01-27 1996-01-24 Ein Chemokin Rezeptor für MCP-1, MIP-1 alpha und/oder RANTES

Country Status (9)

Country Link
US (4) US6150132A (de)
EP (1) EP0805859B2 (de)
JP (2) JP3771585B2 (de)
AT (1) ATE293689T1 (de)
AU (1) AU4455896A (de)
DE (1) DE69634627T3 (de)
ES (1) ES2240989T5 (de)
GB (1) GB9501683D0 (de)
WO (1) WO1996023068A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501683D0 (en) * 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
CA2247989C (en) * 1996-03-01 2010-12-14 Euroscreen S.A. C-c ckr-5,cc-chemokines receptor, derivatives thereof and their uses
US5939320A (en) * 1996-05-20 1999-08-17 New York University G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
US6258527B1 (en) 1996-05-20 2001-07-10 The Aaron Diamond Aids Research Center Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6057102A (en) * 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
US5955303A (en) * 1997-03-06 1999-09-21 Incyte Pharmaceuticals, Inc. Human chemokine receptor-like protein
US6204024B1 (en) 1997-09-12 2001-03-20 Akzo Nobel N.V. CCR5 RNA transcription based amplification assay
US6121023A (en) * 1998-01-22 2000-09-19 Akzo Nobel N.V. Isothermal transcription based assay for the detection and quantification of the chemokine rantes
US6287805B1 (en) 1998-03-20 2001-09-11 Millennium Pharmaceuticals, Inc. Nucleic acid molecules of the protein-coupled heptahelical receptor superfamily and uses therefor
US6420121B1 (en) * 1998-08-31 2002-07-16 Oregon Health Sciences University Prevention of cell migration initiation with CMV US28 receptor antagonists
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
ES2156526B1 (es) * 1999-01-20 2002-02-01 Smithkline Beecham Sa Metabolitos de streptomyces cacaoi como inhibidores de la proteina quimioatrayente de monocitos 1.
DK2270150T4 (da) * 1999-04-09 2019-08-26 Kyowa Hakko Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
JP3707303B2 (ja) * 1999-06-30 2005-10-19 株式会社日立製作所 ヒスタミン計測方法およびヒスタミン計測装置
ATE402192T1 (de) * 2000-03-03 2008-08-15 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
CA2420944A1 (en) 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1325751A4 (de) 2000-10-11 2005-05-04 Daiichi Seiyaku Co Neue medikamente zur behandlung von lebererkrankungen
KR100360410B1 (ko) * 2000-11-14 2002-11-13 삼성전자 주식회사 자기 정렬된 컨택 구조를 갖는 디램 소자와 듀얼 게이트구조의 로직 소자가 복합된 ｍｄｌ 반도체 소자의 제조 방법
AU2002225756A1 (en) * 2000-12-01 2002-06-11 Schering Corporation Uses of mammalian genes and related reagents
AU2002242085A1 (en) * 2001-02-02 2002-08-19 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
WO2002090381A1 (en) * 2001-05-04 2002-11-14 Surromed Inc. Chemokine-binding proteins for treating congestive heart failure
WO2003018549A2 (en) * 2001-08-30 2003-03-06 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
CA2458627C (en) 2001-08-31 2013-09-10 Kyowa Hakko Kogyo Co., Ltd. Human cdr-grafted antibody and antibody fragment thereof
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
US7202249B2 (en) 2002-08-27 2007-04-10 Bristol-Myers Squibb Company Antagonists of chemokine receptors
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5179078A (en) * 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
WO1994007521A1 (en) * 1992-09-28 1994-04-14 Board Of Regents, The University Of Texas System Methods and compositions for treatment of allergic disease
ES2250964T3 (es) * 1992-11-10 2006-04-16 Genentech, Inc. Receptor de la quimioquina c-c(c-c ckr-1).
US5474983A (en) * 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
EP0740701B1 (de) * 1994-01-13 2006-12-06 The Regents of the University of California Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung
GB9501683D0 (en) * 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses

Also Published As

Publication number Publication date
US7183063B2 (en) 2007-02-27
JP3771585B2 (ja) 2006-04-26
WO1996023068A1 (en) 1996-08-01
AU4455896A (en) 1996-08-14
JP2003038191A (ja) 2003-02-12
EP0805859A1 (de) 1997-11-12
US20020187930A1 (en) 2002-12-12
DE69634627T2 (de) 2006-03-02
US20020160015A1 (en) 2002-10-31
ATE293689T1 (de) 2005-05-15
ES2240989T5 (es) 2008-12-16
US6150132A (en) 2000-11-21
US6919432B2 (en) 2005-07-19
ES2240989T3 (es) 2005-10-16
US20050014695A1 (en) 2005-01-20
DE69634627T3 (de) 2008-12-11
EP0805859B1 (de) 2005-04-20
EP0805859B2 (de) 2008-06-25
JPH10513046A (ja) 1998-12-15
GB9501683D0 (en) 1995-03-15
US7655425B2 (en) 2010-02-02

Similar Documents

Publication Publication Date Title
DE69634627D1 (de) Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung
Royer et al. Inhibition of IgE‐induced activation of human mast cells by IL‐10
ES2128544T3 (es) Pirrolopirimidinas como antagonistas del crf.
Ghaemmaghami et al. Human T cell subset commitment determined by the intrinsic property of antigen: the proteolytic activity of the major mite allergen Der p 1 conditions T cells to produce more IL‐4 and less IFN‐γ
Raychaudhuri et al. Nerve growth factor: a key local regulator in the pathogenesis of inflammatory arthritis
BG99605A (en) Antagonists of the growth factor or endothelial cells of the circulatory system
HK1083510A1 (en) Antibodies against pd-1 and uses thereof
DE69813237T2 (de) Zusammensetzungen zur behandlung von durch ccr5 mediatierten erkrankungen
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
ES2138977T3 (es) Agonistas muscarinicos.
DE69425267D1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
TNSN05158A1 (fr) Association destinee au traitement de l'adhd
ATE296799T1 (de) P38-inhibitoren
ATE297755T1 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
Gómez et al. Thorns as induced mechanical defense in a long‐lived shrub (Hormathophylla spinosa, Cruciferae)
ATE197793T1 (de) Tachykinin antagonistes
ATE259230T1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
Banke The dilated TRPA1 channel pore state is blocked by amiloride and analogues
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
ATE78162T1 (de) 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
Tsai et al. Origin of osteoclasts: osteoclast precursor cells
DE60215649D1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
AU1758401A (en) Melanocortin-3 receptor deficient cells, non-human transgenic animals and methods of selecting compounds which regulate body weight
Sabroe et al. The carboxyl terminus of the chemokine receptor CCR3 contains distinct domains which regulate chemotactic signaling and receptor down‐regulation in a ligand‐dependent manner

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings